10x Genomics is trading 4.02% down at $59.94 after biotech shares weakened sharply on September 1, 2026.
- XBI biotech ETF is down 4.24%; Nasdaq Composite and S&P 500 are also lower as investors react to geopolitical tensions, higher oil prices, Treasury yields, and mixed economic data.
- RBC Capital initiated coverage with a Sector Perform rating and a $70 price target; no clearly bearish company-specific announcement was identified.